Real‐World Toxicity Experience With BRAF/MEK Inhibitors in Patients With Erdheim‐Chester Disease

Oncologist - United States
doi 10.1634/theoncologist.2019-0606
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Pediatric Erdheim-Chester Disease With Aggressive Skin Manifestations

British Journal of Dermatology
DermatologyMedicine
2017English

Erdheim-Chester Disease Associated With Marginal Zone Lymphoma and Monoclonal Proteinemia

Case Reports in Hematology
2011English

Successful Lung Transplantation for Pulmonary Disease Associated With Erdheim–Chester Disease

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2017English

Erdheim-Chester Disease With Right Atrial Tumor and “Temporal Arteritis”

Open Journal of Rheumatology and Autoimmune Diseases
2012English

Homonymous Superior Quadrantanopia Due to Erdheim-Chester Disease With Asymptomatic Pituitary Involvement

Case Reports in Neurological Medicine
2017English

Erdheim-Chester Disease Associated With Chronic Myelomonocytic Leukemia Harboring the Same Clonal Mutation

Haematologica
Hematology
2019English

Erdheim Chester Disease: A Trio of Intriguing Cases

Pathology
Forensic MedicinePathology
2020English

Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology
Cancer ResearchOncology
2015English

BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

Hormones and Cancer
OncologyCancer ResearchEndocrinologyAutonomic SystemsEndocrineMetabolismDiabetes
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy